FindTrial
Sign In

A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Parallel-Group, Phase 2 Study of LY3009104 in Japanese Patients with Active Rheumatoid Arthritis on Background Methotrexate Therapy

A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Parallel-Group, Phase 2 Study of LY3009104 in Japanese Patients with Active Rheumatoid Arthritis on Background Methotrexate Therapy

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221667
Enrollment
Unknown
Registered
2011-12-06
Start date
2011-12-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

investigational material(s) Generic name etc : LY3009104 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigat

Sponsors

Eli Lilly Japan K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: at least 6 swollen and at least 6 tender joints based on the 66/68 joint count; ACR functional class I, II, or III

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026